<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/B5DDDF8E-C7DB-4064-88BC-DE21462A7657"><gtr:id>B5DDDF8E-C7DB-4064-88BC-DE21462A7657</gtr:id><gtr:name>Badrilla Limited</gtr:name><gtr:address><gtr:line1>LEEDS INNOVATION CENTRE , 103 CLARENDON ROAD</gtr:line1><gtr:city>LEEDS</gtr:city><gtr:postCode>LS2 9DF</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B5DDDF8E-C7DB-4064-88BC-DE21462A7657" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>B5DDDF8E-C7DB-4064-88BC-DE21462A7657</gtr:id><gtr:name>Badrilla Limited</gtr:name><gtr:address><gtr:line1>LEEDS INNOVATION CENTRE , 103 CLARENDON ROAD</gtr:line1><gtr:city>LEEDS</gtr:city><gtr:postCode>LS2 9DF</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>23711.0</gtr:offerGrant><gtr:projectCost>39519.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/B89DBACB-04E4-4F32-A2BC-48436E4479EE"><gtr:id>B89DBACB-04E4-4F32-A2BC-48436E4479EE</gtr:id><gtr:firstName>John</gtr:firstName><gtr:surname>Colyer</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=700443"><gtr:id>B1938BF2-7D34-462E-ABF1-2BCE238CA0D1</gtr:id><gtr:title>Market and product profiling for diagnostics in kidney injury</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>GRD Proof of Market</gtr:grantCategory><gtr:grantReference>700443</gtr:grantReference><gtr:abstractText>Acute kidney injury (AKI) causes 12,000 preventable deaths per year in England. It affects
14% of people admitted to hospital, extending their hospital stay 2.5fold (&amp;pound;1.2Bn cost per
annum to NHS England) and increasing their chance of death 4-5fold. Better diagnostics are
required to identify AKI patients early. This will permit the focusing of resources on those in
greatest need, and will save lives and money. A definitive diagnostic test for ?early-AKI? does
not yet exist, although a number of promising biomarkers and assays are in development. The
commercial opportunity create by such a diagnostic test is large, &amp;pound;2.25-4.5Bn per annum (1).
Badrilla Ltd has identified an excellent fit between its proprietary technology (US patent
7,939,265) and the technical specifications of improved AKI diagnostic tests. Badrilla Ltd has
assembled an expert team of nephrologists and technologists to create and validate new
diagnostics for the early diagnosis of AKI. The first phase of our collaboration (SMART
PoM) is to define the market and product profile precisely, to focus all subsequent work for
maximum clinical and commercial impact. Phase 1 will review the AKI literature, segment
the field carefully (primary care, secondary care, disease aetiologies and patient stratification),
and integrate this with a map of the commercial and intellectual property landscape for AKI
diagnostics. This will define a clear position for new diagnostic (product) development in
AKI. Finally, we will conduct primary research with clinicians to refine the product profile,
and, with diagnostics companies, to define the deliverables required for initiation of codevelopment
partnerships. This will define the strategy and activities to deploy our
technology in the medical diagnostics sector.
1. Assumptions: test price &amp;pound;12.50; patient population (global) 60million; tests per year per
patient, 3-6.</gtr:abstractText><gtr:fund><gtr:end>2015-06-30</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2014-12-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>23711</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">700443</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>